LONG-TERM RESULTS OF INTERFERON TREATMENT IN HAIRY-CELL LEUKEMIA

被引：12

作者：

CAPNIST, G

FEDERICO, M

CHISESI, T

RESEGOTTI, L

LAMPARELLI, T

FABRIS, P

ROSSI, G

INVERNIZZI, R

GUARNACCIA, C

LEONI, P

LAURIA, F

PAGNUCCO, G

FRASSOLDATI, A

DAMASIO, E

机构：

[1] San Bortolo Hospital, Vicenza University of Modena

[2] Molinette Hospital, Torino

[3] San Martino Hospital, Genova

[4] Regional Hospital, Bolzano

[5] Regional Hospital, Brescia

[6] Cervello Hospital, Palermo

[7] Sant'Orsola Hospital, Bologna

[8] San Matteo Hospital, Pavia

来源：

LEUKEMIA & LYMPHOMA | 1994年 / 14卷 / 5-6期

关键词：

HAIRY CELL LEUKEMIA; INTERFERON;

D O I：

10.3109/10428199409049704

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Eighty nine of 104 patients with hairy cell leukemia (HCL), enrolled between 1985 and 1987 in a multicenter prospective study on human lymphoblastoid IFN alpha-n1, were evaluable for long-term follow-up. The induction treatment, 3 MU/mq daily for a median of 5.7 months, produced a response of 93%, complete + partial response (CR + PR) = 80%, minor (MR) = 13%. Neither prior splenectomy nor pre-treatment variables were associated with the rate of response to IFN. However maintenance treatment of 3 MU/mq weekly given randomly had a highly significant effect on failure free survival (FFS). Of the 43 patients who relapsed, 31/36 (86%) obtained a new response with IFN. No differences in FFS were recorded between first and second response. At the third induction 7/11 patients were treated again with IFN, 4/7 obtaining some response, but the FFS was significantly worse. The overall survival is still 85%. We conclude that (1) IFN should be used as chronic uninterrupted treatment for HCL, (2) reduced dosage is sufficient to prolong the disease free status and (3) continuous lymphoblastoid IFN administration seems not to be associated with the development of resistance to retreatment.

引用

页码：457 / 464

页数：8

共 37 条

[11]

Bememan Z.N., Gastl G., Gangji D., van Camp B., Jochmans K., Aulitzky W., Flamest J., Peetermans M.E., Huber C., Treatment of hairy cell leukemia with recombinant alpha-interferon, Eur. J. Cancer Clin. Oncol., 22, pp. 987-990, (1986)

[12]

Golomb H.M., Fefer A., Golde D.W., Oxer H., Port-Lock R., Silber R., Rappeport J., Ratain M.J., Thompson J., Bonnem E.M., Spiegel R.J., Tensen L., Burke J.S., Vardiman J.W., Sequential evaluation of alpha 2b interferon treatment in 128 patients with hairy cell leukemia, Semin. Oncol., 14, pp. 13-17, (1987)

[13]

Glaspy J.A., Jacobs A.D., Golde D.W., The UCLA experience with type I interferons in hairy cell leukemia, Leukemia, 1, pp. 323-326, (1987)

[14]

Braide I., Hippe E., Hairy cell leukemia treated with interferon alpha 2b, J. Interferon Res., 7, pp. 679-683, (1987)

[15]

Worman C.P., Catovsky D., Cawley J.C., The U.K. experience with human lymphoblastoid interferon in hairy cell leukemia. A report of the First 50 cases, Leukemia, 1, pp. 320-322, (1987)

[16]

Golomb H.M., Ratain M.J., Fefer A., Randomized study of the duration of treatment with interferon alfa 2b in patients with hairy cell leukemia, J. Natl. Cancer Inst., 80, pp. 369-373, (1988)

[17]

Worman C.P., Nethersell A.B., Bottomley J.M., Natural IFN-alpha therapy in hairy cell leukemia (Namalva-type IFN-Wellferon), Klin. Wochenschrift, 65, pp. 685-687, (1987)

[18]

Federico M., Chisesi T., Lauria F., Bernasconi C., Cap-Nist G., Castoldi G., Damasio E., Pagnucco G., Frassol-Dati A., Resegotti L., Silingardi V., Human lymphoblastoid interferon as initial therapy in hairy cell leukemia: A multicentre study in non-splenectomized patients, Br. J. Haematol., 72, pp. 54-56, (1989)

[19]

Glaspy J.A., Marcus S.G., Ambersley J., Golde D.W., Recombinant beta-serine-interferon in hairy cell leukemia compared prospectively with results with recombinant alpha-interferon, Cancer, 64, pp. 409-413, (1989)

[20]

Liberati A.M., Fizzotti M., Di Clemente F., Response to intermediate and standard doses of interferon- beta in hairy cell leukemia, Leuk. Res., 14, pp. 779-784, (1990)

← 1 2 3 4 →